Sana Biotechnology (SANA) EBITDA (2020 - 2026)

Sana Biotechnology (SANA) has 7 years of EBITDA data on file, last reported at -$48.6 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA rose 3.98% year-over-year to -$48.6 million; the trailing twelve-month figure through Mar 2026 stood at -$248.3 million (down 16.78% YoY), and the FY2025 full-year result was -$250.3 million, up 8.21% from the prior year.
• EBITDA improved to -$48.6 million in Q1 2026, from -$61.2 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$2.2 million in Q3 2023 to a low of -$116.3 million in Q2 2023.
• A 5-year average of -$66.9 million and a median of -$61.8 million in 2024 frame the typical range for EBITDA.
• Across the five-year window, EBITDA soared 97.47% in 2023 and plunged 2731.77% in 2024, its largest moves.
• Tracing SANA's EBITDA over 5 years: stood at -$81.8 million in 2022, then slipped by 10.8% to -$90.6 million in 2023, then jumped by 43.87% to -$50.9 million in 2024, then retreated by 20.31% to -$61.2 million in 2025, then gained by 20.56% to -$48.6 million in 2026.
• Business Quant data shows SANA's EBITDA at -$48.6 million in Q1 2026, -$61.2 million in Q4 2025, and -$43.5 million in Q3 2025.